Model 1
|
|---|
Prognostic factor
|
N
1
|
% dead
|
Hazard ratio (95% CI)
|
P
|
CD8 response to Her-2
| | | 0.27 (0.07-1.01) |
0.014
|
Yes | 18 | 17 | | |
No | 20 | 45 | | |
Metastasis
| | | 2.76 (0.65-11.64) | 0.16 |
No | 32 | 28 | | |
Yes | 6 | 50 | | |
Radiotherapy
| | | 0.124 (0.03-0.43) |
0.001
|
Yes | 27 | 19 | | |
No | 13 | 54 | | |
Model 2
|
Prognostic factor
|
N
1
|
% dead
|
Hazard ratio (95% CI)
|
P
|
CD8 response to Her2
| | | 0.27 (0.07-1.01) | 0.052 |
Yes | 18 | 17 | | |
No | 20 | 45 | | |
Metastasis
| | | 2.8 (0.7-10.7) | 0.12 |
No | 32 | 28 | | |
Yes | 6 | 50 | | |
-
1Data for a few patients are missing. Multivariate Cox analysis was performed, where CD8 response to Her2, metastasis and radiotherapy is considered (Model 1), which shows that having no CD8+ T cell response to Her2 has an independent impact on survival (P = 0.014) along with patients who did not receive radiotherapy (P = 0.001) on five-year survival, whereas, in Model 2 no association was observed for no CD8+ T cell responders to Her2 and metastasis. CI, confidence interval; Her2, human epidermal growth factor receptor 2.
